SEPARATION BIOSENSOR FOR PHARMACOLOGICAL APPLICATIONS

Information

  • Research Project
  • 2023004
  • ApplicationId
    2023004
  • Core Project Number
    R44GM052272
  • Full Project Number
    2R44GM052272-02A1
  • Serial Number
    52272
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/10/1995 - 30 years ago
  • Project End Date
    1/31/1999 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    2/1/1997 - 28 years ago
  • Budget End Date
    1/31/1998 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    2
  • Suffix
    A1
  • Award Notice Date
    1/24/1997 - 28 years ago

SEPARATION BIOSENSOR FOR PHARMACOLOGICAL APPLICATIONS

The overall objective of this study is to develop a system that can be used to monitor pharmacokinetic, pharmacological or neurochemical events in near real time. This will be accomplished by coupling microdialysis sampling directly to capillary electrophoresis (CE). The system is much more versatile than conventional biosensors since the sampling and analysis steps can be optimized separately. A system has been developed using CE with LIF detection at 442 nm. In this proposal, an on-line derivatization system will be constructed in order to expand the applicability of the current system for the analysis of primary amines. The development of a shunt probe for portal vein sampling will also be investigated. Lastly, software will be written for near real-time plotting of the data. These three components will form the basis of an instrument which is capable of monitoring and plotting blood levels of a drug in near real time with a temporal resolution of less than one minute. In Phase II, the system will be expanded to include an electrochemical detector. Probes for tissue sampling will also be evaluated. This instrument should find wide applicability in the pharmaceutical and biomedical industries. PROPOSED COMMERCIAL APPLICATION: The system proposed will find commercial application as a drug development tool in the pharmaceutical industry and also for fundamental biomedical research in universities and government laboratories. BAS currently addresses these markets world-wide, and the new system would be compatible with existing BAS products.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    BIOANALYTICAL SYSTEMS, INC. (BASI)
  • Organization Department
  • Organization DUNS
  • Organization City
    WEST LAFAYETTE
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    479061389
  • Organization District
    UNITED STATES